Patents by Inventor Stan Krajewski

Stan Krajewski has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS FOR DETERMINING THE PROGNOSIS FOR PATIENTS WITH A PROSTATE NEOPLASTIC CONDITION
    Publication number: 20100279300
    Abstract: The invention provide a method of identifying a biomarker that is diagnostic for survival of a patient with a prostate neoplastic condition. The method consists of (a) measuring the level of IAPs in a neoplastic prostate cell-containing sample from patients with a prostate neoplastic condition, and (b) identifying a correlation between the level of IAPs in a sample from a patient with the survival of that patient, where the correlation of an IAP with survival in patients indicates the IAP is a biomarker diagnostic of survival of a patient with a prostate neoplastic condition. Also provided is a method of determining a prognosis for survival for a patient with a prostate neoplastic condition. The method consists of (a) measuring the level of XIAP in a neoplastic prostate cell-containing sample from the patient, and (b) comparing the level of XIAP in the sample to a reference level of XIAP, where an increased level of XIAP in the sample correlates with increased survival of the patient.
    Type: Application
    Filed: April 9, 2010
    Publication date: November 4, 2010
    Applicant: BURNHAM INSTITUTE FOR MEDICAL RESEARCH
    Inventors: JOHN C. REED, STAN KRAJEWSKI
  • Methods for determining the prognosis for patients with a prostate neoplastic condition using inhibitor of apoptosis polypeptides
    Patent number: 7704700
    Abstract: The invention provides a method of determining a prognosis for survival for a patient with a prostate neoplastic condition. The method consists of (a) measuring the level of XIAP in a neoplastic prostate cell-containing sample from the patient, and (b) comparing the level of XIAP in the sample to a reference level of XIAP, where an increased level of XIAP in the sample correlates with increased survival of the patient.
    Type: Grant
    Filed: February 12, 2003
    Date of Patent: April 27, 2010
    Assignee: Burnham Institute for Medical Research
    Inventors: John C. Reed, Stan Krajewski
  • METHOD FOR DIAGNOSING CANCER OF THE PROSTATE
    Publication number: 20080227098
    Abstract: Methods for diagnosis and prognosis of prostate cancer are provided. The methods involve the detection of the level of expression of Claudin-1 in tissue or cell samples. Claudin-1 is underexpressed or non-expressed in the majority of prostate cancers.
    Type: Application
    Filed: February 14, 2008
    Publication date: September 18, 2008
    Applicant: Bumham Institute for Medical Research
    Inventors: Maryla Krajewska, John C. Reed, Stan Krajewski
  • METHODS RELATED TO MMP26 STATUS AS A DIAGNOSTIC AND PROGNOSTIC TOOL IN CANCER MANAGEMENT
    Publication number: 20070218512
    Abstract: Disclosed herein are compositions and methods involving identifying MMP-26 in a subject with cancer.
    Type: Application
    Filed: February 28, 2007
    Publication date: September 20, 2007
    Inventors: Alex Strongin, Stan Krajewski, Maryla Krajewski, Alexei Savinov
  • Methods for determining the prognosis for patients with a prostate neoplastic condition
    Publication number: 20030224399
    Abstract: The invention provide a method of identifying a biomarker that is diagnostic for survival of a patient with a prostate neoplastic condition. The method consists of (a) measuring the level of IAPs in a neoplastic prostate cell-containing sample from patients with a prostate neoplastic condition, and (b) identifying a correlation between the level of IAPs in a sample from a patient with the survival of that patient, where the correlation of an IAP with survival in patients indicates the IAP is a biomarker diagnostic of survival of a patient with a prostate neoplastic condition. Also provided is a method of determining a prognosis for survival for a patient with a prostate neoplastic condition. The method consists of (a) measuring the level of XIAP in a neoplastic prostate cell-containing sample from the patient, and (b) comparing the level of XIAP in the sample to a reference level of XIAP, where an increased level of XIAP in the sample correlates with increased survival of the patient.
    Type: Application
    Filed: February 12, 2003
    Publication date: December 4, 2003
    Inventors: John C. Reed, Stan Krajewski